Cargando…
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095015/ https://www.ncbi.nlm.nih.gov/pubmed/37048587 http://dx.doi.org/10.3390/jcm12072503 |
_version_ | 1785023979591827456 |
---|---|
author | Albshesh, Ahmad Bannon, Lian Sharar Fischler, Tali Truyens, Marie Vavricka, Stephan R. Tepes, Katja Pugliese, Daniela Savarino, Edoardo V. Zittan, Eran Drobne, David Roblin, Xavier Bar-Gil Shitrit, Ariella Armuzzi, Alessandro Lobaton, Triana Maharshak, Nitsan Yanai, Henit Ben-Horin, Shomron Kopylov, Uri |
author_facet | Albshesh, Ahmad Bannon, Lian Sharar Fischler, Tali Truyens, Marie Vavricka, Stephan R. Tepes, Katja Pugliese, Daniela Savarino, Edoardo V. Zittan, Eran Drobne, David Roblin, Xavier Bar-Gil Shitrit, Ariella Armuzzi, Alessandro Lobaton, Triana Maharshak, Nitsan Yanai, Henit Ben-Horin, Shomron Kopylov, Uri |
author_sort | Albshesh, Ahmad |
collection | PubMed |
description | Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn’s disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16–22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. Results: Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16–22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6). Conclusion: Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line. |
format | Online Article Text |
id | pubmed-10095015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100950152023-04-13 Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study Albshesh, Ahmad Bannon, Lian Sharar Fischler, Tali Truyens, Marie Vavricka, Stephan R. Tepes, Katja Pugliese, Daniela Savarino, Edoardo V. Zittan, Eran Drobne, David Roblin, Xavier Bar-Gil Shitrit, Ariella Armuzzi, Alessandro Lobaton, Triana Maharshak, Nitsan Yanai, Henit Ben-Horin, Shomron Kopylov, Uri J Clin Med Article Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn’s disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16–22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. Results: Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16–22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6). Conclusion: Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line. MDPI 2023-03-26 /pmc/articles/PMC10095015/ /pubmed/37048587 http://dx.doi.org/10.3390/jcm12072503 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Albshesh, Ahmad Bannon, Lian Sharar Fischler, Tali Truyens, Marie Vavricka, Stephan R. Tepes, Katja Pugliese, Daniela Savarino, Edoardo V. Zittan, Eran Drobne, David Roblin, Xavier Bar-Gil Shitrit, Ariella Armuzzi, Alessandro Lobaton, Triana Maharshak, Nitsan Yanai, Henit Ben-Horin, Shomron Kopylov, Uri Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title | Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_full | Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_fullStr | Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_full_unstemmed | Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_short | Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
title_sort | comparison of short- and long-term effectiveness between anti-tnf and ustekinumab after vedolizumab failure as first-line therapy in crohn’s disease: a multi-center retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095015/ https://www.ncbi.nlm.nih.gov/pubmed/37048587 http://dx.doi.org/10.3390/jcm12072503 |
work_keys_str_mv | AT albsheshahmad comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT bannonlian comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT shararfischlertali comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT truyensmarie comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT vavrickastephanr comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT tepeskatja comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT pugliesedaniela comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT savarinoedoardov comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT zittaneran comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT drobnedavid comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT roblinxavier comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT bargilshitritariella comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT armuzzialessandro comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT lobatontriana comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT maharshaknitsan comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT yanaihenit comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT benhorinshomron comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy AT kopylovuri comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy |